



## REVIEW ARTICLE

# Nuclear Magnetic Resonance technique in tumor metabolism

Ting Li <sup>a</sup>, Pengchi Deng <sup>b,\*</sup>

<sup>a</sup> College of Chemistry, Sichuan University, Chengdu, China

<sup>b</sup> Analytical & Testing Center, Sichuan University, Chengdu, China

Received 11 September 2016; accepted 5 December 2016

Available online 13 December 2016

## KEYWORDS

High resolution Magic Angle Spinning; Metabolomics; Multivariate data analysis; NMR technique; Tumor metabolism

**Abstract** Cancer is one of the most serious diseases that cause an enormous number of deaths all over the world. Tumor metabolism has great discrimination from that of normal tissues. Exploring the tumor metabolism may be one of the best ways to find biomarkers for cancer detection, diagnosis and to provide novel insights into internal physiological state where subtle changes may happen in metabolite concentrations. Nuclear Magnetic Resonance (NMR) technique nowadays is a popular tool to analyze cell extracts, tissues and biological fluids, etc, since it is a relatively fast and an accurate technique to supply abundant biochemical information at molecular levels for tumor research. In this review, approaches in tumor metabolism are discussed, including sample collection, data profiling and multivariate data analysis methods etc. Some typical applications of NMR are also summarized in tumor metabolism.

Copyright © 2016, Chongqing Medical University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

Cancer nowadays is a major public health problem in the world. The occurrence of cancer is increasing because of the growth and aging of the population, as well as increasing formed risk factors such as dirty air, polluted

water, overweight, smoking, too much pressure in life.<sup>1</sup> Based on GLOBOCAN estimates, about 14.1 million new cancer cases and 8.2 million deaths occurred in 2012.<sup>2</sup> In China, it has been estimated that there are up to 3 million new cases and over 2 million deaths. More seriously, the cancer death rate will continue to increase without effective therapeutic options. Fortunately, some diagnostic methods and techniques are already widely used in clinic, such as chest radiograph,<sup>3,4</sup> fiberoptic bronchoscopy,<sup>5</sup> Computed Tomography (CT) scan,<sup>6,7</sup> Magnetic Resonance Imaging (MRI)<sup>8,9</sup> and positron-emission tomography (PET),<sup>10</sup> etc. Although they can provide helpful information about

\* Corresponding author.

E-mail address: [pcdeng@yahoo.com](mailto:pcdeng@yahoo.com) (P. Deng).

Peer review under responsibility of Chongqing Medical University.

the size and location of the tumors, combining two or even more of these methods, they provide little information about metabolic profiling of the tumors.<sup>11,12</sup> It is vitally crucial for analyzing biomarkers at the molecular level for tumor diagnosis, monitoring and treatment.<sup>13–15</sup> Therefore, some effective complementary methods are especially valuable and challenging to investigate tumor metabolic profiling.

Metabolomics is a fast growing field of research downstream of transcriptomics, genomics, which mainly involves the multicomponent analysis of cell extracts, tissues and biological fluids.<sup>16–20</sup> It provides a snapshot of the metabolic dynamics that reflect the response of living systems to both pathophysiological stimuli and/or genetic alteration.<sup>21–23</sup> It has been reported that tumor metabolism differs from that of normal tissue.<sup>24,25</sup> Exploring the tumor metabolome may be the best way to reveal the phenotypic changes relative to biological function, especially where subtle changes in metabolite concentrations can be tractable.<sup>26</sup> In general, the primary analytical techniques used in metabolomics are Mass Spectrometry (MS)<sup>27–29</sup> and Nuclear Magnetic Resonance (NMR).<sup>30–32</sup> NMR is a non-destructive and non-invasive technique that can provide complete structural analysis of an extensive range of organic molecules in complex mixtures,<sup>33,34</sup> thus, can be used to differentiate metabolism between tumor and healthy tissues, aiming at finding possible biomarkers of presence and/or degree of different cancers such as brain,<sup>35</sup> prostate,<sup>36</sup> breast,<sup>37</sup> liver,<sup>38</sup> renal<sup>39</sup> and esophageal<sup>40</sup> cancer.

## NMR technique analytical platform

NMR has been employed as an excellent tool in exploring tumor metabolism due to its advantages, such as non-invasive, non-destructive, highly reproducible, providing real-time detection for biological samples near the physiological environment,<sup>41,42</sup> offering both qualitative and quantitative information of compounds in complex mixtures precisely and exquisite spectral editing technique make the method flexible and efficient.<sup>43,44</sup> NMR technique can use not only  $^1\text{H}$  spectra but also other nuclei like  $^{13}\text{C}$ ,  $^{15}\text{N}$  and  $^{31}\text{P}$  etc. to obtain helpful information about the tumor metabolic pathways.<sup>45–47</sup> These spectroscopies have pretty wide spectral width, meaning low possibility of signal overlapping, but their low sensitivity also limit their application, although some metabolites contain phosphorus and nitrogen.<sup>48</sup> Because of high sensitivity and almost all compounds contain proton in biological tissues,  $^1\text{H}$ -NMR is the most widely used method to differentiate metabolism between tumor and normal tissues.<sup>32,49</sup>

Fig. 1 shows a standard workflow of tumor metabolism studies by NMR, including sample collection, data profiling, pattern recognition and final validation.<sup>50</sup> NMR spectroscopy combined with pattern recognition technique is a vitally helpful tool in tumor metabolic profiling as it has the potential to obtain comprehensive characteristics and pathways between tumor and healthy tissues.<sup>36,51–53</sup> Usually, final results may supply abundant biochemical information at molecular levels for further tumor research, aiming at effectively promoting the process of early diagnosis and treatment of tumor control.

## Sample preparation

NMR-based metabolomics has been performed to study a range of different biofluids types including plasma,<sup>54</sup> serum,<sup>55</sup> urine,<sup>56</sup> cerebrospinal fluid,<sup>57</sup> saliva,<sup>58</sup> and feces.<sup>59</sup> Intact tissues and cells samples can also be analyzed by NMR technique.<sup>60–62</sup> To validate those data, sample collection, storage and processing procedures are extremely critical.<sup>63,64</sup> For example, some deuterated buffer should be added to adjust the pH value to avoid the systematic bias by different pH values.<sup>65,66</sup> Typically, urine, serum and plasma samples should be stored in appropriate conditions after collection to reduce sample degradation from multiple freeze/thaw cycles.<sup>67,68</sup> Biofluids and tissue samples should be stored at or below  $-70\text{ }^\circ\text{C}$ .<sup>69</sup> Blood plasma or serum samples have high protein content which will obscure the resonances of small molecule metabolites. Therefore, it is necessary to physically remove proteins prior to analysis, which is done by precipitation or extractant or to weaken the intensity of protein resonances in the  $^1\text{H}$ -NMR spectrum due to their faster rates of  $T_2$  relaxation.<sup>70,71</sup> In addition, samples collected from a group of volunteers should be careful to minimize and account for effects from factors such as gender, age, diet, fasting state, exercise, and physical activity.<sup>72–74</sup>

## Data analysis

NMR and MS both have been employed as common analytical tools in tumor metabolism research. NMR data can be quantitatively analyzed more directly, while MS technique has higher sensitivity. One-dimensional NMR spectroscopy of biological samples usually has hundreds of peaks, so it is a big challenge to obtain all its useful information.<sup>75–77</sup> Therefore, it is vitally helpful to combine the pattern recognition. Several multivariate statistical analysis methods can be employed to discriminate metabolites between complex systems such as principle component analysis (PCA), hierarchical cluster analysis (HCA), partial least squares (PLS), discriminant function analysis (DFA) and artificial neural networks (ANN).<sup>78–80</sup>

As a kind of unsupervised methods, PCA is the most widely used statistical analysis methods in metabolomics which can reveal outliers, groups and trends in the original dataset effectively.<sup>81,82</sup> It reduces the multidimensional data space into a much lower dimensional model space while converting the dataset in two matrices, so called scores and loadings. The result shows how samples related to each other and performs the variable contribution to the classification results. PCA can identify the largest variation in the dataset, but the latent variables responsible for the class separation may not be in the direction of the largest variation.<sup>83,84</sup> Instead, orthogonal partial least squares discriminant analysis (OPLS-DA), a very powerful supervised method in metabolomics is a regression model that reflects the correlation between multivariate data and dependent variables with class information. In OPLS-DA, a single component is used as a predictor to describe the separation between classes, where the other components are orthogonal variations to reflect the separation within classes. OPLS-DA emphasizes separations between classes, reduces separation within class at the same time.<sup>85–88</sup> Therefore,




Fig. 1 Tumor metabolism studies by NMR.

an OPLS-DA scores plot will have tighter clusters with a larger separation between groups compared to PCA.<sup>89</sup> Usually, supervised and unsupervised multivariate statistical techniques are commonly used together to provide a deep explanation of the different metabolite concentrations between experimental groups.

## NMR databases

The great challenge of NMR-based metabolomics is to recognize obtained peaks which can be assigned to different compounds.<sup>15</sup> Nowadays, there are a number of public databases available to promote the identification of metabolites including the Human Metabolome Database (HMDB),<sup>90</sup> Biological Magnetic Resonance Data Bank,<sup>91</sup> NMR database of Linköping, Magnetic Resonance Metabolomics

Database and Madison-qingdao Metabolomics Consortium Database (MMCD).

These databases can be time-saving in metabolite identification and facilitate the validation of relevant biological pathways. HMDB, the most comprehensive curative human metabolite database in the world, provides a comprehensive compound description, names, structural information, reference NMR spectra, biofluids concentrations, pathway information and other public databases.<sup>92</sup>

## Applications of NMR technique in tumor metabolism

In the following sections, we summarized some typical applications of NMR in various tumor metabolomics. To facilitate systematization and comparison of those studies,

Table 1 shows an overview of the main cancer-related metabolic findings in different cancer types.

## Colorectal cancer

Colorectal cancer (CRC) is one of the most prevalent tumor types. Understanding the metabolic profile of colorectal tumor is important for therapeutic approaches and molecular diagnosis. Amiot et al<sup>94</sup> investigated the fecal metabolic phenotype of patients with advanced colorectal tumor and controls using <sup>1</sup>H-NMR and multivariate modeling. PCA results showed that advanced colorectal tumor demonstrated increased fecal concentrations of four short-chain fatty acids (valerate, acetate, propionate and butyrate) and decreased signals relating to  $\beta$ -glucose, Gln, and glutamate. The prediction accuracy of the method is higher than that of the guaiac-fecal occult blood test and the Wif-1 methylation test. Beatriz et al<sup>102</sup> performed high resolution Magic Angle Spinning (HR-MAS) NMR to analyze metabolites in intact tumor samples and samples of adjacent mucosa obtained from colorectal cancer patients. The results indicated marked biochemical differences between the two types of tissues by PCA and OPLS-DA. Moreover, metabolic profiles were able to differentiate tumors of different T- and N-stages (T stage has greater weight than

the N stage and the former affects survival more significantly) on the basis of tumor node metastasis (TNM) classification. Bertini et al used NMR to profile the serum metabolome in patients with metastatic colorectal cancer (mCRC) and determine whether a disease marker may exist that is strong enough to predict overall survival (OS).<sup>103</sup> In the validation set, supervised predictive models allowed a separation of 96.7% of patients from the healthy controls. Wang et al<sup>104</sup> applied PCA, PLS-DA and OPLS-DA to analyze the <sup>1</sup>H-NMR profiling data to identify the distinguishing metabolites of rectal cancer. Results showed excellent separation among the different stages of rectal cancer tissues and normal controls. These modified metabolites revealed disturbance of energy, amino acids, ketone body and choline metabolism, which may be correlated with the progression of human rectal cancer. Piotto et al<sup>105</sup> applied HR-MAS NMR to characterize the metabolic fingerprint of both tumoral and normal tissue samples obtained from a cohort of patients affected by primary colorectal cancer. By analyzing the data using PLS-DA revealed that tumor tissue samples are richer in taurine, glutamate, aspartate and lactate whereas normal tissues contain a higher amount of myo-inositol and  $\beta$ -glucose. The statistical model was subsequently used to perform a blind test on tumor and healthy tissue.

**Table 1** Main cancer-related metabolic findings in different cancer types unveiled by NMR technique.

Cancer type	Sample	Metabolic changes in cancer VS controls	Reference
Colorectal	Serum	(+) acetate, acetoacetate, 3-hydroxybutyrate, lactate, pyruvate (-) glucose, myo-inositol, taurine, dimethylglycine	Ludwig et al <sup>93</sup>
	Fecal extracts	(+) acetate, valerate, propionate, butyrate (-) $\beta$ -glucose, Gln, glutamate	Amiot et al <sup>94</sup>
	Biopsies	(+) taurine, glutamate, aspartate, lactate (-) myo-inositol, $\beta$ -glucose	Piotto et al <sup>95</sup>
Liver	Serum	(+) acetate, N-acetylglycoproteins, Gln, glycerol, $\alpha$ -ketoglutarate, 1-methylhistidine, Phe, pyruvate, Tyr (-) acetoacetate, Cho, LDL, VLDL, Val	Gao et al <sup>96</sup>
	Urine	(+) carnitine, creatine (-) acetone, creatinine, glycine, hippurate, TMAO	Shariff et al <sup>97</sup>
Lung	Plasma	(+) lactate, VLDL, LDL, pyruvate (-) acetate, alanine, citrate, formate, Gln, HDL, His, methanol, Tyr, Val	Rocha et al <sup>54</sup>
	Urine	(+) N-acetylglutamine, citrate, creatinine, 3-hydroxyisobutyrate, 3-hydroxyisovalerate (-) hippurate, trigonellinamide, trigonelline	Carrola et al <sup>98</sup>
Breast	Tissues	Changes in Cho, creatine, $\beta$ -glucose, GPC, glycine, myo-inositol, PCho, taurine	Bathe et al <sup>99</sup>
	Serum	Metastatic vs early disease: (+) acetoacetate, glycerol, pyruvate, mannose, glutamate, 3-hydroxybutyrate, N-acetylglycoproteins, (-) His, alanine, betaine	Elodie et al <sup>100</sup>
Pancreatic	Serum	(+) soleucine, triglyceride, leucine, creatinine (-) 3-hydroxybutyrate, 3-hydroxyisovalerate, lactate, TMAO	Ouyang et al <sup>55</sup>
	Plasma	(+) N-acetyl glycoprotein, DMA, VLDL, acetone (-) lactate, 3-hydroxybutyrate, HDL, LDL, citrate, glutamate, alanine, Gln, His, isoleucine, lysine, Val	Lin et al <sup>101</sup>

Abbreviations: Cho, choline; Tyr, tyrosine; Val, valine; His, Histidine; Phe, phenylalanine; PCho, phosphocholine; GPC, glycerol-phosphocholine; Gln, glutamine; DMA, dimethylamine; HDL, high density lipoprotein; LDL, low density lipoprotein; TMAO, trimethylamine N-oxide; VLDL, very low density lipoprotein; (+) increased in cancer, (-) decreased in cancer relatively to control.

## Breast cancer

Breast cancer (BC) is the globally highest incidence and mortality form of all malignant diseases in women and its recurrence rate is also very high. More than three quarters of BC patients can achieve a high survival rate if the cancer is diagnosed at its early stage. It is imperative to identify markers for BC diagnosis and management including prediction, early diagnosis and individualized treatment. Li et al examined 31 breast tissue samples (13 cancer, 9 benign and 9 normal) obtained by core needle biopsy using multivariate modeling.<sup>106</sup> Although it was impossible to distinguish the benign tumors and normal tissues, cancer and non-cancer samples can be discriminated well with OPLS-DA on the NMR spectra. A subsequent blind test showed 69% sensitivity and 94% specificity in the prediction of the tumor status. Beathe et al compared the metabolic profiles of tissues collected from 85 breast cancer patients, where the concentration levels of GPC, PC and choline were monitored carefully.<sup>99</sup> The concentrations of choline and glycine were much higher in tumor samples larger than 2 cm compared with smaller tumors samples, indicating that HR-MAS NMR could be an efficient tool for BC diagnosis with the ability to identify cancer stages. Then they performed Electronic Reference to access In vivo Concentrations (ERETIC) applying with HR-MAS NMR to quantify metabolites in intact BC samples.<sup>107</sup> The nine significant discriminatory metabolites were b-glucose, lactate, glycine, myo-inositol, taurine, GPC, PC, choline and creatine. Elodie et al attempted to identify metabolic serum changes associated with advanced metastatic breast cancer (MBC) in comparison to the localized early disease (EBC).<sup>100</sup> The results clearly distinguished EBC and MBC samples with 89.8% sensitivity and 79.3% specificity, where higher levels of serum concentrations of acetoacetate, 3-hydroxybutyrate, glycerol, pyruvate, mannose, N-acetylglycoproteins, glutamate and lower concentration of histidine, alanine and betaine metabolites were observed in MBC tissues. Giskeodegard et al conducted biopsies which were excised during surgery and analyzed by HR-MAS NMR from BC patients.<sup>108</sup> The data were analyzed by PLS-DA, probabilistic neural networks (PNNs) and Bayesian belief networks (BBNs). It was also found that estrogen and progesterone receptor status can be successfully predicted to improve predictions of the hormonal therapy of breast carcinomas. Vincent et al employed a combination of NMR and MS methods to build and validate a model for early BC recurrence detection based on a set of 257 retrospective serial samples.<sup>109</sup> Utilizing the model, over 55% patients recurrence could be detected as early as 13 months before the recurrence was diagnosed.

## Lung cancer

Lung cancer is one of the most serious health problems, also the most common cause of cancer death. There has been a large amount of research in the field. Claudia et al applied PCA and HCA followed by <sup>1</sup>H-NMR resulted in good discrimination between tumor and non-involved tissues, showing that inherently different metabolic profiling characterize the two tissue types.<sup>54</sup> In a similar study, NMR was utilized

to measure metabolites in urine from lung cancer patients and control healthy group.<sup>110</sup> The multivariate modeling of urinary profiles discriminate the two groups, where the Monte Carlo Cross Validation of the classification model highlighted 93% sensitivity, 94% specificity and an overall classification rate of 93.5%. Liu et al conducted a new algorithm named PSO-SVWL-PLSDA to rectify the weakened efficacy by the high similarity of metabolic profiles combined with <sup>1</sup>H-NMR metabonomics.<sup>111</sup> Data clustering in discriminative metabolites for the lung cancer diagnosis were lactate, glucose, threonine, valine, taurine, trimethylamine, Gln, glycoprotein, proline and lipid. Chen et al performed the metabonomic characteristics of 51 lung tissues from 17 patients with lung cancer using the <sup>1</sup>H-NMR and the multivariate data analysis methods.<sup>112</sup> The findings clearly disclosed metabonomic characteristics of lung cancer tissues at various sites. Durate et al searched for the metabolic markers of lung cancer in urine by combining analysis of the NMR data including PCA, PLS-DA, and OPLS-DA.<sup>113</sup> The obtained results showed a high level of sensitivity and 100% specificity. Moreover, PLS-DA of a subset of tumour samples allowed adenocarcinomas to be discriminated from carcinoid tumors and epidermoid carcinomas, showing differences in metabolite levels between these histological types. Jordan et al investigated discrimination between tissue and serum metabolites for squamous cell carcinoma (SCC) and adenocarcinoma (AC) in the lung tumors by HR-MAS NMR.<sup>114</sup> The results disclosed the potential to differentiate between the tested lung cancer types and controls. Rocha et al investigated the variations in the metabolic profile of blood plasma from lung cancer patients and control group by NMR-based metabonomics.<sup>115</sup> PLS-DA modeling of CPMG spectra from plasma, subjected to Monte Carlo Cross Validation provided the potential of this approach to screen and diagnose for lung cancer. The distinguishing metabolites between the patients and the control group were lower levels of HDL, higher levels of VLDL and LDL. The patients' plasma had significantly high level of lactate and pyruvate but significantly low levels of citrate, formate, acetate, glucose, Gln, alanine, tyrosine and valine.

## Liver cancer

Hepatocellular carcinoma (HCC) is a leading cancer worldwide in terms of incidence and mortality, for the lack of surveillance of patients. Yang et al compared metabolite levels in sera of HCC tumor and non-involved adjacent liver tissues by HR-MAS NMR.<sup>116</sup> The discriminating candidate biomarkers were lactate, amino acids including glutamate, glutamine, Gly, leucine and alanine, Cho, PC, GPC, triglycerides, glucose, phosphorylethanolamine and glycogen. Gao et al monitored the changes in endogenous metabolites of liver cirrhosis (LC) and HCC using single blood samples.<sup>96</sup> Results indicated a higher level of acetate, pyruvate, Gln, a-ketoglutarate, glycerol, tyrosine, 1-methylhistidine and phenylalanine, together with lower level of LDL, isoleucine, Val, acetoacetate, creatine, Cho and unsaturated lipids in HCC patients. Moreover, pathway analysis suggested altered energy metabolism with changes in the tricarboxylic acid (TCA) cycle in LC and HCC patients. In a similar study, Nahon et al compared the metabolic profiles from

154 cirrhotic patients with and without HCC.<sup>117</sup> The result indicated that serum NMR spectra combined with the OPLS analysis model provided an evident discrimination between cirrhotic and large HCC tumors. Perturbations observed in the synthesis of glutaminolysis, citrate cycle, phospholipid and glycolysis metabolism have potential to assess pathological hepatic lesions. Debra et al investigated the metabolic profiles from primary HCC, cirrhotic tissues (CIR), hepatic metastases from colorectal carcinomas and non-cirrhotic normal tissues by <sup>1</sup>H-NMR combined with pattern-recognition and visualization techniques.<sup>117</sup> Results indicated clear metabolic differences in the studied grades and the tissue signals of lactate and the glucose were primarily discriminate the different histological samples, which can be of great benefit to liver tumor diagnosis. Antonio et al obtained NMR spectroscopy of 51 needle biopsies (14 primary nodules, 14 recurrent, and 23 paired cirrhotic specimens) to elucidate the metabolite changes associated with HCC.<sup>118</sup> The results clearly differentiated primary HCC from recurrences using PLS-DA models and disclosed alterations in choline metabolism.

## Pancreatic cancer

Pancreatic cancer is a malignant tumor. Once diagnosed, surgical cure is no longer an efficient option for most patients, thus early detection of pancreatic cancer is vital for its treatment. OuYang et al studied the serum collected from pancreatic cancer patients with NMR.<sup>55</sup> Results showed good distinction between cancer and benign group. The analysis were revealed by higher level of soleucine, leucine and creatinine and lower values of 3-hydroxybutyrate, 3-hydroxyisovalerate, lactate, triglyceride and TMAO from pancreatic cancer patients compared to control group. These metabolite changes could be used as metabolic markers for the early detection of pancreatic cancer. Oliver et al analyzed the sera from pancreatic cancer patients and healthy volunteers by <sup>1</sup>H-NMR followed by statistical analyses.<sup>119</sup> The diagnostic model distinguished benign from malignant pancreatic lesions accurately via excluding patients with overt diabetes mellitus. Lin et al used <sup>1</sup>H-NMR spectra to profile the plasma metabolites obtained from 19 pancreatic cancer patients.<sup>101</sup> The levels of N-acetyl glycoprotein, DMA, VLDL and acetone in the PC group increased, whereas lactate, 3-hydroxybutyrate, HDL, LDL, alanine, glutamate, Gln, His, isoleucine, lysine and valine were found to be reduced.

## Conclusions and future perspectives

NMR technique has become one of the most powerful tools in biology and medicine research. On the basis of the combination of <sup>1</sup>H-NMR spectroscopy with pattern recognition methods of multivariate data analysis, metabolomics can provide comprehensive characteristics of the major metabolic pathways to evaluate the status of the tumor more precisely. Therefore, NMR application in tumor metabolomics research could have a great potential to provide valuable information about early diagnosis, treatment options, processes and prognosis estimate of cancer and other serious diseases. Nowadays, NMR sensitivity has

been greatly improved by higher magnetic field, cryoprobe, fast 2D NMR experiments, polarization transfer etc., so NMR technique can be more widely applied in tumor metabolomics studies.

## Conflicts of interest

All authors have none to declare.

## References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics. *CA A Cancer J Clin.* 2015;65(1):5–29.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics. *CA A Cancer J Clin.* 2012; 65(2):87–108.
3. Oken MM, Hocking WG, Kvale PA, et al. Screening by chest radiograph and lung cancer mortality: the prostate, lung, colorectal, and ovarian (plco) randomized trial. *JAMA.* 2011; 306(17):1865–1873.
4. Oken MM, Marcus PM, Hu P, et al. Baseline chest radiograph for lung cancer detection in the randomized prostate, lung, colorectal and ovarian cancer screening trial. *J Natl Cancer Inst.* December 21, 2005;97(24):1832–1839.
5. Karahalli E, Yilmaz A, Türker H, Özvaran K. Usefulness of various diagnostic techniques during fiberoptic bronchoscopy for endoscopically visible lung cancer: should cytologic examinations be performed routinely? *Respiration.* 2001;68(6): 611–614.
6. Berrington de González A, Mahesh M, Kim K, et al. Projected cancer risks from computed tomographic scans performed in the United States in 2007. *Archives Intern Med.* 2009;169(22): 2071–2077.
7. Berrington de González A, Kim KP, Berg CD. Low-dose lung computed tomography screening before age 55: estimates of the mortality reduction required to outweigh the radiation-induced cancer risk. *J Med Screen.* September 1, 2008; 15(3):153–158.
8. Padhani AR, Liu G, Mu-Koh D, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. *Neoplasia.* 2009;11(2):102–125.
9. Chenevert TL, McKeever PE, Ross BD. Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. *Clin Cancer Res.* September 1, 1997;3(9):1457–1466.
10. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. *N Engl J Med.* 2006;354(5): 496–507.
11. Yi CA, Lee KS, Lee HY, et al. Coregistered whole body magnetic resonance imaging-positron emission tomography (MRI-PET) versus PET-computed tomography plus brain MRI in staging resectable lung cancer. *Cancer.* 2013;119(10): 1784–1791.
12. Erasmus JJ, Sabloff BS. CT, positron emission tomography, and MRI in staging lung cancer. *Clin Chest Med.* 2008;29(1): 39–57.
13. Sugimoto M, Wong DT, Hirayama A, Soga T, Tomita M. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. *Metabolomics.* 2010;6(1):78–95.
14. Claudino WM, Goncalves PH, di Leo A, Philip PA, Sarkar FH. Metabolomics in cancer: a bench-to-bedside intersection. *Crit Rev Oncol Hematol.* 2012;84(1):1–7.
15. Patel S, Ahmed S. Emerging field of metabolomics: big promise for cancer biomarker identification and drug discovery. *J Pharm Biomed Anal.* 2015;107:63–74.

16. Yizhak K, Benyamini T, Liebermeister W, Ruppin E, Shlomi T. Integrating quantitative proteomics and metabolomics with a genome-scale metabolic network model. *Bioinformatics*. June 15, 2010;26(12):i255–i260.
17. Nicholson JK, Wilson ID. High resolution proton magnetic resonance spectroscopy of biological fluids. *Prog Nucl Magnetic Reson Spectrosc*. 1989/01/01;21(4):449–501.
18. Nambiar PR, Gupta RR, Misra V. An “Omics” based survey of human colon cancer. *Mutat Res Fundam Mol Mech Mutagen*. 11/10/2010;693(1–2):3–18.
19. Raamsdonk LM, Teusink B, Broadhurst D, et al. A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. *Nat Biotechnol*. 2001;19(1):45–50.
20. Bino RJ, Hall RD, Fiehn O, et al. Potential of metabolomics as a functional genomics tool. *Trends Plant Sci*. 2004;9(9):418–425.
21. Kell DB. Systems biology, metabolic modelling and metabolomics in drug discovery and development. *Drug Discov Today*. 2006;11(23):1085–1092.
22. Nicholson JK, Lindon JC, Holmes E. ‘Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. *Xenobiotica*. 1999/01/01;29(11):1181–1189.
23. Dunn WB, Broadhurst DI, Atherton HJ, Goodacre R, Griffin JL. Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. *Chem Soc Rev*. 2011/01;40(1):387–426.
24. Bathen TF, Sitter B, Sjøbakk TE, Tessem M-B, Gribbestad IS. Magnetic resonance metabolomics of intact tissue: a biotechnological tool in cancer diagnostics and treatment evaluation. *Cancer Res*. 2010/09;70(17):6692–6696.
25. Yang J, Xu G, Zheng Y, et al. Diagnosis of liver cancer using HPLC-based metabonomics avoiding false-positive result from hepatitis and hepatocirrhosis diseases. *J Chromatogr B*. 2004;813(1):59–65.
26. Griffin JL, Shockcor JP. Metabolic profiles of cancer cells. *Nat Rev Cancer*. 2004;4(7):551–561.
27. Woo HM, Kim KM, Choi MH, et al. Mass spectrometry based metabolomic approaches in urinary biomarker study of women’s cancers. *Clin Chim Acta*. 2009;400(1):63–69.
28. Zürgbig P, Mischak H. *Capillary Electrophoresis Coupled to Mass Spectrometry for Biomarker Discovery and Diagnosis of Kidney Diseases*. 2008.
29. Kolch W, Neusüß C, Pelzing M, Mischak H. Capillary electrophoresis–mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. *Mass Spectrom Rev*. 2005;24(6):959–977.
30. Zhang J, Wei S, Liu L, et al. NMR-based metabolomics study of canine bladder cancer. *Biochimica Biophysica Acta (BBA) – Mol Basis Dis*. 2012;1822(11):1807–1814.
31. Gebregiworgis T, Powers R. Application of NMR metabolomics to search for human disease biomarkers. *Comb Chem High Throughput Screen*. 2012;15(8):595–610.
32. Zira AN, Theocharis SE, Mitropoulos D, Migdalis V, Mikros E. <sup>1</sup>H NMR metabonomic analysis in renal cell carcinoma: a possible diagnostic tool. *J Proteome Res*. 2010;9(8):4038–4044.
33. Yang C, Richardson AD, Osterman A, Smith JW. Profiling of central metabolism in human cancer cells by two-dimensional NMR, GC-MS analysis, and isotopomer modeling. *Metabolomics*. 2008;4(1):13–29.
34. de Graaf RA, Behar KL. Quantitative <sup>1</sup>H NMR spectroscopy of blood plasma metabolites. *Anal Chem*. 2003;75(9):2100–2104.
35. Wilson M, Davies NP, Brundler M-A, McConville C, Grundy RG, Peet AC. High resolution magic angle spinning <sup>1</sup>H NMR of childhood brain and nervous system tumours. *Mol Cancer*. 2009;8(1):1–11.
36. DeFeo EM, Wu C-L, McDougal WS, Cheng LL. A decade in prostate cancer: from NMR to metabolomics. *Nat Rev Urol*. 2011;8(6):301–311.
37. Denkert C, Bucher E, Hilvo M, et al. Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery. *Genome Med*. 2012;4(4):37.
38. Li CW, Kuo YC, Chen CY, et al. Quantification of choline compounds in human hepatic tumors by proton MR spectroscopy at 3T. *Magnetic Reson Med*. 2005;53(4):770–776.
39. Tosi MR, Tugnoli V, Bottura G, Lucchi P, Battaglia A, Giorgianni P. Biochemical characterization of human renal tumors by in vitro nuclear magnetic resonance. *J Mol Struct*. 5/30/2001;565–566:323–327.
40. Zhang X, Xu L, Shen J, et al. Metabolic signatures of esophageal cancer: NMR-based metabolomics and UHPLC-based focused metabolomics of blood serum. *Biochimica Biophysica Acta (BBA) – Mol Basis Dis*. 2013;1832(8):1207–1216.
41. Dumas M-E, Maibaum EC, Teague C, et al. Assessment of analytical reproducibility of <sup>1</sup>H NMR spectroscopy based metabolomics for large-scale epidemiological research: the INTERMAP Study. *Anal Chem*. 2006;78(7):2199–2208.
42. Gil AM, de Pinho PG, Monteiro MS, Duarte IF. NMR metabolomics of renal cancer: an overview. *Bioanalysis*. 2015/09/01;7(18):2361–2374.
43. Liu M, Nicholson JK, Lindon JC. High-resolution diffusion and relaxation edited one-and two-dimensional <sup>1</sup>H NMR spectroscopy of biological fluids. *Anal Chem*. 1996;68(19):3370–3376.
44. Martin-Pastor M. Experiments for the editing of singlet peaks and simplification of <sup>1</sup>H NMR spectra of complex mixtures. *J Agric food Chem*. 2014;62(5):1190–1197.
45. Katz-Brull R, Margalit R, Bendel P, Degani H. Choline metabolism in breast cancer; <sup>2</sup>H-, <sup>13</sup>C- and <sup>31</sup>P-NMR studies of cells and tumors. *Magnetic Reson Mater Phys Biol Med*. 1998;6(1):44–52.
46. Daly PF, Lyon RC, Faustino PJ, Cohen JS. Phospholipid metabolism in cancer cells monitored by <sup>31</sup>P NMR spectroscopy. *J Biol Chem*. 1987;262(31):14875–14878.
47. Shanaiah N, Desilva MA, Gowda GN, Raftery MA, Hainline BE, Raftery D. Class selection of amino acid metabolites in body fluids using chemical derivatization and their enhanced <sup>13</sup>C NMR. *Proc Natl Acad Sci*. 2007;104(28):11540–11544.
48. Emwas A-HM, Salek RM, Griffin JL, Merzaban J. NMR-based metabolomics in human disease diagnosis: applications, limitations, and recommendations. *Metabolomics*. 2013;9(5):1048–1072.
49. Duarte IF, Gil AM. Metabolic signatures of cancer unveiled by NMR spectroscopy of human biofluids. *Prog Nucl Magnetic Reson Spectrosc*. 2012;62:51–74.
50. Ah Zhang, Sun H, Qiu S, Xj Wang. NMR-based metabolomics coupled with pattern recognition methods in biomarker discovery and disease diagnosis. *Magnetic Reson Chem*. 2013;51(9):549–556.
51. Tiziani S, Lopes V, Günther UL. Early stage diagnosis of oral cancer using <sup>1</sup>H NMR–based metabolomics. *Neoplasia*. 2009;11(3), 269–IN210.
52. Jordan KW, Cheng LL. NMR-based metabolomics approach to target biomarkers for human prostate cancer. *Expert Rev Proteomics*. 2007;4(3):389–400.
53. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. *Cell Metab*. 2008;7(1):11–20.
54. Rocha CM, Carrola J, Barros AS, et al. Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of blood plasma. *J Proteome Res*. 2011;10(9):4314–4324.
55. OuYang D, Xu J, Huang H, Chen Z. Metabolomic Profiling of serum from human pancreatic cancer patients using <sup>1</sup>H NMR spectroscopy and principal component analysis. *Appl Biochem Biotechnol*. 2011;165(1):148–154.

56. Slupsky CM, Steed H, Wells TH, et al. Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. *Clin Cancer Res.* 2010;16(23):5835–5841.
57. Dunne VG, Bhattachayya S, Besser M, Rae C, Griffin JL. Metabolites from cerebrospinal fluid in aneurysmal subarachnoid haemorrhage correlate with vasospasm and clinical outcome: a pattern-recognition  $^1\text{H}$  NMR study. *NMR Biomed.* 2005;18(1):24–33.
58. Wei J, Xie G, Zhou Z, et al. Salivary metabolite signatures of oral cancer and leukoplakia. *Int J Cancer.* 2011;129(9):2207–2217.
59. Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B. Metabolite profiling of fecal water extracts from human colorectal cancer. *NMR Biomed.* 2009;22(3):342–348.
60. Tomlins AM, Foxall PJ, Lindon JC, et al. High resolution magic angle spinning  $^1\text{H}$  nuclear magnetic resonance analysis of intact prostatic hyperplastic and tumour tissues. *Anal Commun.* 1998;35(3):113–115.
61. Beckonert O, Coen M, Keun HC, et al. High-resolution magic-angle-spinning NMR spectroscopy for metabolic profiling of intact tissues. *Nat Protoc.* 2010;5(6):1019–1032.
62. Somashekar BS, Kamarajan P, Danciu T, et al. Magic angle spinning NMR-based metabolic profiling of head and neck squamous cell carcinoma tissues. *J Proteome Res.* 2011;10(11):5232–5241.
63. Sykes BD. Urine stability for metabolomic studies: effects of preparation and storage. *Metabolomics.* 2007;3(1):19–27.
64. Bernini P, Bertini I, Luchinat C, Nincheri P, Staderini S, Turano P. Standard operating procedures for pre-analytical handling of blood and urine for metabolomic studies and biobanks. *J Biomol NMR.* 2011;49(3–4):231–243.
65. Brown SA, Simpson AJ, Simpson MJ. Evaluation of sample preparation methods for nuclear magnetic resonance metabolic profiling studies with *Eisenia fetida*. *Environ Toxicol Chem.* 2008;27(4):828–836.
66. Reily MD, Robosky LC, Manning ML, Butler A, Baker JD, Winters RT. DFTMP, an NMR reagent for assessing the near-neutral pH of biological samples. *J Am Chem Soc.* 2006;128(38):12360–12361.
67. Grimes JH, O'Connell TM. The application of micro-coil NMR probe technology to metabolomics of urine and serum. *J Biomol NMR.* 2011;49(3–4):297–305.
68. Canelas AB, Ras C, Ten Pierick A, van Dam JC, Heijnen JJ, Van Gulik WM. Leakage-free rapid quenching technique for yeast metabolomics. *Metabolomics.* 2008;4(3):226–239.
69. Briscoe CJ, Hage DS. Factors affecting the stability of drugs and drug metabolites in biological matrices. *Bioanalysis.* 2009.
70. Tiziani S, Emwas A-H, Lodi A, et al. Optimized metabolite extraction from blood serum for  $^1\text{H}$  nuclear magnetic resonance spectroscopy. *Anal Biochem.* 2008;377(1):16–23.
71. Psychogios N, Hau DD, Peng J, et al. The human serum metabolome. *PLoS One.* 2011;6(2):e16957.
72. Rasmussen LG, Savorani F, Larsen TM, Dragsted LO, Astrup A, Engelsen SB. Standardization of factors that influence human urine metabolomics. *Metabolomics.* 2011;7(1):71–83.
73. Beger RD. A review of applications of metabolomics in cancer. *Metabolites.* 2013;3(3):552–574.
74. Emwas A-H, Luchinat C, Turano P, et al. Standardizing the experimental conditions for using urine in NMR-based metabolomic studies with a particular focus on diagnostic studies: a review. *Metabolomics.* 2015;11(4):872–894.
75. Wang J, Zhang S, Li Z, et al.  $^1\text{H}$ -NMR-based metabolomics of tumor tissue for the metabolic characterization of rat hepatocellular carcinoma formation and metastasis. *Tumor Biol.* 2011;32(1):223–231.
76. Jonsson P, Johansson AI, Gullberg J, et al. High-throughput data analysis for detecting and identifying differences between samples in GC/MS-based metabolomic analyses. *Anal Chem.* 2005/09/01;77(17):5635–5642.
77. Madsen R, Lundstedt T, Trygg J. Chemometrics in metabolomics—a review in human disease diagnosis. *Anal Chim Acta.* 2010;659(1):23–33.
78. Kohl SM, Klein MS, Hochrein J, Oefner PJ, Spang R, Gronwald W. State-of-the art data normalization methods improve NMR-based metabolomic analysis. *Metabolomics.* 2012;8(1):146–160.
79. Liu S-Y, Zhang R-L, Kang H, Fan Z-J, Du Z. Human liver tissue metabolic profiling research on hepatitis B virus-related hepatocellular carcinoma. *World J Gastroenterology WJG.* 2013;19(22):3423–3432.
80. Snow PB, Smith DS, Catalona WJ. Artificial neural networks in the diagnosis and prognosis of prostate cancer: a pilot study. *J Urol.* 1994;152(5 Pt 2):1923–1926.
81. Lehnhardt FG, Bock C, Röhn G, Ernestus RI, Hoehn M. Metabolic differences between primary and recurrent human brain tumors: a  $^1\text{H}$  NMR spectroscopic investigation. *NMR Biomed.* 2005;18(6):371–382.
82. Gribbestad IS, Petersen SB, Fjøsne HE, Kvinnsland S, Krane J.  $^1\text{H}$  NMR spectroscopic characterization of perchloric acid extracts from breast carcinomas and non-involved breast tissue. *NMR Biomed.* 1994;7(4):181–194.
83. Bylesjö M, Rantalainen M, Cloarec O, Nicholson JK, Holmes E, Trygg J. OPLS discriminant analysis: combining the strengths of PLS-DA and SIMCA classification. *J Chemom.* 2006;20(8-10):341–351.
84. Goodpaster AM, Romick-Rosendale LE, Kennedy MA. Statistical significance analysis of nuclear magnetic resonance-based metabolomics data. *Anal Biochem.* 2010;401(1):134–143.
85. Westerhuis JA, van Velzen EJ, Hoefsloot HC, Smilde AK. Multivariate paired data analysis: multilevel PLS-DA versus OPLS-DA. *Metabolomics.* 2010;6(1):119–128.
86. Molteni CG, Cazzaniga G, Condorelli DF, Fortuna CG, Biondi A, Musumarra G. Successful application of OPLS-DA for the discrimination of wild-type and mutated cells in acute lymphoblastic leukemia. *QSAR Comb Sci.* 2009;28(8):822–828.
87. Boccard J, Rutledge DN. A consensus orthogonal partial least squares discriminant analysis (OPLS-DA) strategy for multi-block Omics data fusion. *Anal Chim Acta.* 2013;769:30–39.
88. Ramadan Z, Jacobs D, Grigorov M, Kochhar S. Metabolic profiling using principal component analysis, discriminant partial least squares, and genetic algorithms. *Talanta.* 2006;68(5):1683–1691.
89. Worley B, Halouska S, Powers R. Utilities for quantifying separation in PCA/PLS-DA scores plots. *Anal Biochem.* 2013;433(2):102–104.
90. Wishart DS, Tzur D, Knox C, et al. HMDB: the human metabolome database. *Nucleic acids Res.* 2007;35(suppl 1):D521–D526.
91. Ulrich E, Akutsu H, Doreleijers J, et al. BioMagResBank. *Nucleic Acids Res.* 2008;36:D402–D408.
92. Forsythe IJ, Wishart DS. Exploring human metabolites using the human metabolome database. *Curr Protoc Bioinforma.* 2009;14.18.11–14.18.45.
93. Ludwig C, Ward D, Martin A, et al. Fast targeted multidimensional NMR metabolomics of colorectal cancer. *Magnetic Reson Chem MRC.* 2009;47:S68–S73.
94. Amiot A, Dona AC, Wijeyesekera A, et al.  $^1\text{H}$  NMR spectroscopy of fecal extracts enables detection of advanced colorectal neoplasia. *J Proteome Res.* 2015/09/04;14(9):3871–3881.
95. Piotto M, Moussallieh F-M, Dillmann B, et al. Metabolic characterization of primary human colorectal cancers using high resolution magic angle spinning  $^1\text{H}$  magnetic resonance spectroscopy. *Metabolomics.* 2009;5.



96. Gao H, Lu Q, Liu X, et al. Application of  $^1\text{H}$  NMR-based metabolomics in the study of metabolic profiling of human hepatocellular carcinoma and liver cirrhosis. *Cancer Sci.* 2009;100(4):782–785.
97. Shariff MI, Gomaa AI, Cox IJ, et al. Urinary metabolic biomarkers of hepatocellular carcinoma in an Egyptian population: a validation study. *J Proteome Res.* 2011;10(4):1828–1836.
98. Carrola J, CuM Rocha, AnS Barros, et al. Metabolic signatures of lung cancer in biofluids: NMR-based metabolomics of urine. *J Proteome Res.* 2010;10(1):221–230.
99. Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, Gribbestad IS. Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. *NMR Biomed.* 2006;19(1):30–40.
100. Jobard E, Pontoizeau C, Blaise BJ, Bachelot T, Elena-Herrmann B, Trédan O. A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer. *Cancer Lett.* 2/1/2014;343(1):33–41.
101. Zhang L, Jin H, Guo X, et al. Distinguishing pancreatic cancer from chronic pancreatitis and healthy individuals by  $^1\text{H}$  nuclear magnetic resonance-based metabolomic profiles. *Clin Biochem.* 2012;45(13–14):1064–1069.
102. Jiménez B, Mirnezami R, Kinross J, et al.  $^1\text{H}$  HR-MAS NMR spectroscopy of tumor-induced local metabolic “field-effects” enables colorectal cancer staging and prognostication. *J Proteome Res.* 2013/02/01;12(2):959–968.
103. Bertini I, Cacciatore S, Jensen BV, et al. Metabolomic NMR fingerprinting to identify and predict survival of patients with metastatic colorectal cancer. *Cancer Res.* January 1, 2012; 72(1):356–364.
104. Wang H, Wang L, Zhang H, et al.  $^1\text{H}$  NMR-based metabolic profiling of human rectal cancer tissue. *Mol Cancer.* 2013; 12(1):1–12.
105. Piotto M, Moussallieh F-M, Dillmann B, et al. Metabolic characterization of primary human colorectal cancers using high resolution magic angle spinning  $^1\text{H}$  magnetic resonance spectroscopy. *Metabolomics.* 2008;5(3):292–301.
106. MuLan L, Yonghyun S, Nariya C, et al. An HR-MAS MR metabolomics study on breast tissues obtained with core needle biopsy. *PLoS One.* 2011;6(10):1–8.
107. Sitter B, Bathen TF, Singstad TE, et al. Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy. *NMR Biomed.* 2010; 23(4):424–431.
108. Giskeødegård GF, Grinde MT, Sitter B, et al. Multivariate modeling and prediction of breast cancer prognostic factors using mr metabolomics. *J Proteome Res.* 2010/02/05;9(2): 972–979.
109. Asiago VM, Alvarado LZ, Shanaiah N, et al. Early detection of recurrent breast cancer using metabolite profiling. *Cancer Res.* November 1, 2010;70(21):8309–8318.
110. Carrola J, Rocha CM, Barros AS, et al. Metabolic signatures of lung cancer in biofluids: NMR-based metabolomics of urine. *J Proteome Res.* 2011/01/07;10(1):221–230.
111. Liu Y-F, Xu S, Gong H, Cui Y-F, Song D-D, Zhou Y-P. Partial least-squares discriminant analysis optimized by particle swarm optimization: application to  $^1\text{H}$  nuclear magnetic resonance analysis of lung cancer metabolomics. *J Chemom.* 2015;29(10):537–546.
112. Chen W, Zu Y, Huang Q, et al. Study on metabolomic characteristics of human lung cancer using high resolution magic-angle spinning  $^1\text{H}$  NMR spectroscopy and multivariate data analysis. *Magnetic Reson Med.* 2011;66(6): 1531–1540.
113. Duarte IF, Rocha CM, Barros AS, et al. Can nuclear magnetic resonance (NMR) spectroscopy reveal different metabolic signatures for lung tumours? *Virchows Arch.* 2010;457(6): 715–725.
114. Jordan KW, Adkins CB, Su L, et al. Comparison of squamous cell carcinoma and adenocarcinoma of the lung by metabolomic analysis of tissue–serum pairs. *Lung Cancer.* 2010; 68(1):44–50.
115. Rocha CM, Barros AS, Gil AM, et al. Metabolic profiling of human lung cancer tissue by  $^1\text{H}$  high resolution magic angle spinning (HRMAS) NMR spectroscopy. *J Proteome Res.* 2010/01/04;9(1):319–332.
116. Yang Y, Li C, Nie X, et al. Metabolomic studies of human hepatocellular carcinoma using high-resolution magic-angle spinning  $^1\text{H}$  NMR Spectroscopy in conjunction with multivariate data analysis. *J Proteome Res.* 2007/07/01;6(7): 2605–2614.
117. Nahon P, Amathieu R, Triba MN, et al. Identification of serum proton NMR metabolomic fingerprints associated with hepatocellular carcinoma in patients with alcoholic cirrhosis. *Clin Cancer Res.* December 15, 2012;18(24):6714–6722.
118. Solinas A, Chessa M, Culeddu N, et al. High resolution-magic angle spinning (HR-MAS) NMR-based metabolomic fingerprinting of early and recurrent hepatocellular carcinoma. *Metabolomics.* 2013;10(4):616–626.
119. Bathe OF, Shaykhtudinov R, Kopciuk K, et al. Feasibility of Identifying pancreatic cancer based on serum metabolomics. *Cancer Epidemiol Biomark Prev.* January 1, 2011;20(1): 140–147.